• Email Alerts
  • Careers
  • Contact Us

SCYNEXIS, Inc.

  • Home
  • About Us
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partnerships
    • Careers
    • Contact
  • Pipeline
    • Ibrexafungerp Development Pipeline
    • Clinical Trials
    • Vulvovaginal Candidiasis
    • Invasive Candidiasis
    • Invasive Aspergillosis
    • Refractory Invasive Fungal Infections
  • Science
    • SCYNEXIS Research Platform
    • Publications and Presentations
    • Expanded Access
  • News
    • Press Releases
    • Events
  • Investors
    • Overview
    • News Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Stock Data
    • FAQs

Press Releases

Investors

Investors

  • Overview
  • News Releases
    • Press Releases
    • Email Alerts
  • Events & Presentations
    • IR Calendar
    • Presentations
  • Governance
    • Leadership
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Financials & Filings
    • SEC Filings
    • Annual Reports
    • Proxy Statements
    • Quarterly Results
    • Key Ratios
  • Stock Data
    • Quote
    • Historical Data
    • Investor Calculator
    • Analyst Coverage
    • Ownership Profile
  • FAQs
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
  • News Releases

  • Press Releases
  • Email Alerts

SCYNEXIS to Present at the BIO Digital International Convention 2020

Jun 8, 2020

SCYNEXIS Strengthens Leadership Team with Appointment of Jim Maffezzoli as Vice President of Marketing and Sales

Jun 2, 2020

SCYNEXIS Reports First Quarter 2020 Financial Results and Provides Company Update

May 11, 2020

SCYNEXIS Announces Six Abstracts Published by 30th ECCMID Highlighting the Potential Clinical Utility of Ibrexafungerp

May 6, 2020

SCYNEXIS to Participate in Antifungals Panel at Maxim Group’s Infectious Disease Virtual Conference: The Renaissance of the Anti-infective Sector

Apr 28, 2020

SCYNEXIS Announces Positive Top-Line Results from its Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection)

Apr 21, 2020

SCYNEXIS and Aspire Capital Enter into $20 Million Common Stock Purchase Agreement

Apr 13, 2020

SCYNEXIS Secures $10 Million in Financing through Senior Convertible Note Purchase Agreement with Puissance Capital

Apr 9, 2020

SCYNEXIS to Virtually Present on the Candida Auris Treatment Landscape at the 22nd Annual Superbugs and Superdrugs Conference 2020

Mar 26, 2020

SCYNEXIS Reports Full Year 2019 Financial Results and Provides Company Update

Mar 11, 2020
RSS
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...13

    1 Evertrust Plaza, Jersey City, NJ 07302
    (201) 884-5485
    View Google Map

    © 2021 SCYNEXIS, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap Contact Us